Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company’s first two PRE-ICO, medical marijuana-based pharmacies are currently undergoing building inspections, and the Company is conducting final tests on all systems from inventory through final sale. Additionally, CBIS is planning the integration of iCannabinoid, the Company’s state-of-the-art social media and educational interactive online platform into the CBIS Pharmacy openings.
“The buildouts are pretty much done, and these stores are beautiful, touch-screen, state-of-the-art facilities,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “The Company management should be proud, as we will soon conduct pre-opening, live testing of an interactive set of iCannabinoid My Health Modules that will enable users to track personal health goals and milestones, and many other items relating to personal health maintenance. There will also be medical, action-tracking support Action Groups for heart monitoring, pain monitoring, eating, sleep monitoring, exercise monitoring, and many more groups that can be created and customized to fit the personal needs of users.”
As we prepare to open our first CBIS-Branded Pharmacies, plans are well underway for the development of the much-anticipated, CBIS Manufacturing and Distribution Complex. CBIS’ quality assurance program will also be applied to the development and distribution of new and exciting products that will be developed and released on-demand for self-medicating patients. This type of manufacturing and distribution facility will enable CBIS to distribute its products to its flagship pharmacies and to CBIS’ patients faster, in much larger volumes, and in a very cost-effective manner. This complex will complement the operations of the CBIS Pharmacies and will be part of the Company’s infrastructure that will support the expansion of CBIS Pharmacies throughout California.
“As its own and only using certified manufacturers and producers of the raw materials required for its manufacturing processes, CBIS will ensure that efficient and cost-effective standards are applied to the production of its current products, including pills, extracts, creams, tinctures, and sprays,” stated Dr. Allen Herman, CBIS’ Chief Medical Officer. “CBIS expects iCannabinoid to be the premier online platform for all things Cannabinoid-related, and will provide diverse real-time information and value to pharmacy shoppers, create a community of patients, advocates, doctors, researchers, parents, lawyers, growers, journalists, government and private-sector leaders, community organizers, and other interested parties.”
iCannabinoid Ambassador Program: Whether you are a successful doctor, a patient, a dispensary, a grower, an activist, a lawyer or you just plain want to help! It really doesn’t matter because of the multiple information channels the system allows for. The only limitation is your imagination. iCannabinoid Ambassadors will be knowledgeable, professional, and available to answer any questions Members may have relating to their area of expertise.
If you are looking to just plain help out, apply today and become a Certified iCannabinoid Ambassador, please visit:
The iCannabinoid, My Health platform is for those seeking real-time information and looking to track personal or multiple patient interactive group usage for alternative cannabinoid treatments targeting various critical ailments and palliative care for such cases as Cancer, Pain, Arthritis, Parkinson’s Disease, Anxiety, Multiple Sclerosis, and so much more. iCannabinoid is designed to be a conduit to provide timely and relevant information for Cannabinoid users to share with each other 24/7 online and in-store pharmacies.
iCannabinoid My Health Modules are a significant feature in iCannabinoid that allows members to set up fully integrated personal health modules for tracking health records and set goals.
Easy access and editable modules are provided for Members to create medication lists, monitor dosage results, monitor heart rate and blood pressure:
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
Contact Information Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer email@example.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder firstname.lastname@example.org Tel: 1-888-263-0832